SCHEDULE: Allogene Therapeutics: Dr. Chang's Ownership Update
Beneficial Ownership Report
Dr. David D. Chang and affiliated trusts updated their beneficial ownership in Allogene Therapeutics, Inc., collectively holding 5.0% of common stock.
Summary
- David D. Chang, M.D., Ph.D., and three affiliated family trusts (Chang 2006 Family Trust, JEC 2019 Trust, RTC 2019 Trust) have filed an Amendment No. 4 to their Schedule 13G, updating their beneficial ownership in Allogene Therapeutics, Inc.
- As of June 30, 2025, Dr. Chang, individually and through the trusts, collectively beneficially owns 11,136,728 shares of Allogene Therapeutics' common stock.
- This aggregate ownership represents 5.0% of the company's common stock, calculated based on 218,730,809 shares outstanding as of May 9, 2025.
- Dr. Chang's beneficial ownership includes 5,413,414 shares issuable within 60 days from June 30, 2025, upon the exercise of stock options.
Sentiment
Score: 6
Explanation: The filing is a routine beneficial ownership disclosure, indicating a significant and stable stake by a key individual and affiliated trusts, which can be viewed as a neutral to slightly positive signal of confidence.
Positives
- Significant beneficial ownership by a key individual (Dr. David D. Chang) and affiliated trusts, indicating continued alignment with shareholder interests.
- Dr. Chang's beneficial ownership includes a substantial number of stock options, suggesting a vested interest in future share price appreciation.
Negatives
- No specific negative financial or operational information is disclosed in this beneficial ownership filing.
Risks
- No specific company-related risks are detailed in this beneficial ownership report.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing is a routine disclosure of beneficial ownership by a significant shareholder and does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- Beneficial ownership includes shares held by family trusts (Chang 2006 Family Trust, JEC 2019 Trust, RTC 2019 Trust) where Dr. David D. Chang serves as co-trustee.
Stakeholder Impact
- Provides transparency to shareholders regarding significant beneficial ownership by a key individual and affiliated entities, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date as of which 218,730,809 shares of common stock were reported outstanding. |
| 05/13/2025 | Date of Issuer's Quarterly Report on Form 10-Q. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/08/2025 | Date of filing of this Schedule 13G Amendment No. 4 and Joint Filing Agreement. |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain information related to the company's financial performance, strategic direction, or operational updates that would warrant a change in investment recommendation. It primarily provides transparency on a significant insider's stake.
Keywords
Allogene Therapeutics, Beneficial Ownership, Schedule 13G, David D. Chang, Common Stock, Shareholder, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.